Gene therapy approaches for intervertebral disc degeneration

Spine

Volumn 29, Issue 23, 2004, Pages 2770-2778

  Shimer, Adam L ^a   Chadderdon, Robert C ^a   Gilbertson, Lars G ^a   Kang, James D ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Kaufmann Building ^*  (United States)

Author keywords

Biological treatment; Bone morphogenic protein; Degenerative disc disease; Gene therapy; Gene transfer; Growth factors; Intervertebral disc; Transforming growth factor; Viral vector

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; COMPLEMENTARY DNA; GROWTH FACTOR; LIM PROTEIN; LIM PROTEIN 1; PROTEOGLYCAN; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VIRUS VECTOR;

DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRACELLULAR MATRIX; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERVERTEBRAL DISK DEGENERATION; MEDICAL RESEARCH; NONHUMAN; NUCLEUS PULPOSUS; PRIORITY JOURNAL; PUBLICATION; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GROWTH SUBSTANCES; HUMANS; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DISPLACEMENT;

EID: 14844365979     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.brs.0000146455.11253.08     Document Type: Review

References (62)

1. Luo X, Pietrobon R, Sun SX, et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79-86.
2. Karasek M, Bogduk N. Twelve-month follow-up of a controlled trial of intradiscal thermal anuloplasty for back pain due to internal disc disruption. Spine 2000-25:2601-7.
3. Sambrook PN, MacGregor AJ, Specror TD. Genetic influences of cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins. Arthritis Rheum 1999;42:366-72.
4. Pluijm SM, van Essen HW, Bravenboer N, et al. Collagen type I alpha1 Sp1 polymorphism, osteoporosis, and intervertebral disc degeneration in older men and women. Ann Rheum Dis 2004;63:71-7.
5. Noponen-Hietala N, Kyllonen E, Mannikko M, et al. Sequence variations in the collagen IX and XI genes are associated with degenerative lumbar spinal srenosis. Ann Rheum Dis 2003;62:1208-14.
6. Kelsey JL, Githens PB, Walter SD, et al. An epidemiological study of acute prolapsed cervical intervertebral disc. J Bone Joint Surg Am 1984;66A:907-14.
7. Buckwalter JA. Aging and degeneration of the human intervertebral disc. Spine 1995;20:1307-14.
8. Pearce RH, Grimmer BJ, Adams ME. Degeneration and the chemical composition of the human lumbar intervertebral disc. J Orthop Res 1987;5:198-205.
9. Urban JP, McMullin JF. Swelling pressure of the intervertebral disc: Influence of proteoglycan and collagen contents. Biorbeology 1985;22:145-57.
10. Urban JP, McMullin JF. Swelling pressure of the lumbar intervertebral discs: Influence of age, spinal level, composition, and degeneration. Spine 1988;13: 179-87.
11. Ahlgren BD, Vasavada A, Brower RS, et al. Annular incision technique on the strength and multidirectional flexibility of the healing intervertebral disc. Spine 1994;19:948-54.
12. Kazarian LE, Creep characteristics of the human spinal column. Orthop Clin North Am 1975;6:3-18.
13. Kang JD, Georgescu HI, McIntyre-Larkin L, et al. Herniated lumber intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine 1996;21:271-7.
14. Thompson JP, Oegema TR Jr, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine 1991;16:253-60.
15. Li J, Ki KS, Park JS, et al. BMP-2 and CDMP-2: stimulation of chondrocyte production of proteoglycan. J Orthop Sci 2003;8:829-35.
16. Takegami K, Masuda K, Kumano F, et al. Osteogenic protein-1 is most effective in stimulating nucleus pulposus and annulus fibrosus cells to repair their matrix after chondroitinase ABC-induced chemonucleolysis. Transcripts f the Proceedings of the 45th Annual Meeting of the Orthopaedic Research Society; Anaheim, California; 1999.
17. Matsumoto T, An H, Thonar E, et al. Effect of osteogenic protein-1 on the metabolism of proteoglycan of intervertebral disc cells in aging. Transcripts of the Proceedings of the 48th Annual Meeting of the Orthopaedic Research Society; Dallas, Texas; 2002.
18. Franceschi RT, Wang D, Krebsbach PH, et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000;78:476-86.
19. Ratko TA, Cummings JP, Blebea J, et al. Clinical gene therapy for nonmalignant disease. Am J Med 2003;115:560-9.
20. Moon SH, Gilbertson LG, Nishida K, et al. Human intervertebral disc cells are genetically modifiable by adenovirus-mediated gene transfer. Spine 2000; 25:2573-9.
21. Nishida K, Kang JD, Suh JK, et al. Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration. Spine 1999;23:2437-42; discussion 2443.
22. Nishida K, Kang JD, Gilbertson LG, et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine 1999;24:2419-25.
23. Lattermann C. Characterization of gene transfer into nucleus pulposus cells using a new viral delivery system in vivo and in vitro. Spine 2004. In press.
24. Moon SH, Nishida K, Gilbertson LG, et al. Responsiveness of human intervertebral disc cells to adenovirus mediated transfer of TGF-β1 cDNA in 2D and 3D culture systems: comparison to exogenous TGF-β1. Presented at: International Society for the Study of the Lumbar Spine meeting; Adelaide, Australia; 2002.
25. Paul R, Haydon RC, Cheng H, et al. Potential use of sox9 gene therapy for intervertebral disc degenerative disease. Spine 2003;28:775-63.
26. Ferguson SJ, Steffen T. Biomechanics of the aging spine. Eur Spine J 2003; 12(suppl 2):S97-103.
27. Trout JJ, Buckwalter JA, Moore KC, et al. Ultrastructure of the human intervertebral disc. I. Changes in notochordal cells with age. Tissue Cell 1982;14:359-69.
28. Oegema TR Jr. The role of disc cell heterogeneity in determining disc biochemistry: a speculation. Biochem Soc Trans 2002;30(Pt 6):839-44.
29. Vernon-Roberts B. The Biology of the intervertebral Disc. Vol. II. Ghosh P, ed. Boca Raton, FL: CRC Press; 1988:73-119.
30. Handa T, Ishihara H, Ohshima H, et al. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase, nitric oxide, interleukin-6, and prostaglandin E2. Spine 1996;21:271-7.
31. Martinek V, Ueblacker P, Imhoff AB. Current concepts of gene therapy and cartilage repair. J Bone Joint Surg Br 2003;85:782-8.
32. Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res 1996;14:690-9.
33. Takegami K, Thonar EJ, An HS, et al. Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to IL-1. Spine 2002;27:1318-25.
34. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972;175:949-55.
35. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci 2003;92:203-17.
36. Goldstein SA. In vivo nonviral delivery factors to enhance bone repair. Clin Orthop 2000;(379 suppl):S113-9.
37. Park J, Ries J, Gelse K, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Cette Ther 2003;10:1089-98.
38. Wehling P, Schulitz KP, Robbins PD, et al. Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy. Spine 1997;22:1092-7.
39. Sobajima S, Kim JS, Gilbertson LG, et al. Gene therapy for degenerative disc disease. Gene Ther 2004;11:390-401.
40. Moon S, Nishida K, Gilbertson LG, et al. Biologic response of human intervertebral disc cell to gene therapy cocktail. Presented at: Orthopaedic Research Society meeting; San Francisco, California; 2001.
41. Wallach CJ, Sobajima S, Watanabe Y, et al. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from human intervertebral discs. Spine 2003;28:2331-7.
42. Boden SD, Liu Y, Hair G, et al. LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 1998;139:5125-34.
43. Boden SD, Titus L, Hair G, et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 1998; 23:2486-92.
44. Yoon ST, Kim KS, Li J, et al. Gene therapy with LMP-1 increases intervertebral disc cell proteoglycan production and changes cell phenotype. Presented at: International Society for the Study of the Lumbar Spine meeting; Cleveland, Ohio; 2002.
45. Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2:545-50.
46. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E-1 deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
47. Park JB, Chang H, Kim KW. Expression of Fas ligand and apoptosis of disc cells herniated lumbar disc tissue. Spine 2001;26:618-21.
48. Takada T, Nishida K, Doita M, et al. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine 2002;27:1526-30.
49. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
50. Griffith TS, Brunner T, FIetcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
51. Brennan AL, Geddes DM. Bringing new treatments to the bedside in cystic fibrosis. Pediatr Pulmonol 2004;37:87-98.
52. Anderson DG, Izzo MW, Hall DJ, et al. Comparative gene expression profiling of normal and degenerative discs: analysis of a rabbit annular laceration model. Spine 2002;27:1291-6.
53. Behrens A, Haigh J, Mechta-Grigoriou F, et al. Impaired intervertebral disc formation in the absence of Jun. Development 2003;130:103-9.
54. Gruber HE, Hanley EN Jr. Ultrastructure of the human intervertebral disc during aging and degeneration: comparison of surgical and control specimens. Spine 2002;27:798-805.
55. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
56. Caplan AI, Elyaderani M, Mochizuki Y, et al. Principles of cartilage repair and regeneration. Clin Orthop 1997;342:254-69.
57. Liu L, Wang G, Lee K, et al. Expression of soluble TNF-RII from transduced human mesenchymal stem cells: in vitro and in vivo efficacy. Blood 1999:94.
58. Nomura T, Mochida J, Okuma M, et al. Nucleus pulposus allograft retards intervertebral disc degeneration. Clin Orthop 2001;389:94-101.
59. Okuma M, Mochida J, Nishimura K, et al. Reinsertion of stimulated nucleus pulposus cells retards intervertebral disc degeneration: an in vitro and in vivo experimental study. J Orthop Res 2000;18:988-97.
60. Sakai D, Mochida J, Yamamoto Y, et al. Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials 2003;24:3531-41.
61. National Institutes of Health Office of Biotechnology Activities, Available at: http://www4.od.nih.gov/oba/. Accessed January 2004.
62. Wiley Journal of Gene Medicine. Available at: http://www.wiley.co.uk/ genetherapy/. Accessed February 2003.